Commentary on A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation: Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

✍ Scribed by Donald L. Trump

• Book ID: 116956599
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 94 KB
• Volume: 27
• Category: Article
• ISSN: 1078-1439
• DOI: 10.1016/j.urolonc.2009.07.005